Core Viewpoint - Weitai Medical-B (2235.HK) has received approval from the National Medical Products Administration for its core product, the Equil insulin pump, expanding its use to children and adolescents aged 3-17 years, thus providing new treatment options for millions of diabetic patients in China [1] Group 1: Product Approval and Market Expansion - The Equil insulin pump was previously approved only for adult diabetes patients, and the recent approval allows it to be used for a younger demographic [1] - This expansion in indications demonstrates the company's strong independent R&D capabilities in the field of diabetes monitoring, treatment, and management [1] - The approval is expected to strengthen the company's leading position in the industry and strategically expand the market space for its products [1] Group 2: Future Focus and Innovation - The company plans to continue focusing on the global development of diabetes monitoring, treatment, and management methods [1] - There will be ongoing efforts to drive technological and product innovation in related fields [1]
港股异动丨微泰医疗盘中涨超6% 贴敷式胰岛素泵儿童及青少年适应症获批